gms | German Medical Science

72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

06.06. - 09.06.2021

Quantification of PpIX-fluorescence of cerebral breast cancer metastases

Quantifizierung der PpIX-Fluoreszenz zerebraler Brustkrebs-Metastasen

Meeting Abstract

Suche in Medline nach

  • presenting/speaker Johannes Knipps - Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Marion Rapp - Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Daniel Hänggi - Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Michael Sabel - Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Marcel A. Kamp - Universitätsklinikum Düsseldorf, Klinik für Neurochirurgie, Düsseldorf, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 72. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Polnischen Gesellschaft für Neurochirurgie. sine loco [digital], 06.-09.06.2021. Düsseldorf: German Medical Science GMS Publishing House; 2021. DocP062

doi: 10.3205/21dgnc350, urn:nbn:de:0183-21dgnc3505

Veröffentlicht: 4. Juni 2021

© 2021 Knipps et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objective: Introduction of the 5-ALA technique is one major advance in neuro-oncological surgery. Protoporphyrin IX (PpIX)-fluorescence was observed in about half of cerebral metastases. For now, no study found a correlation between the dichotomized PpIX-fluorescence of breast cancer metastases and neither the receptor status nor the histological subtype of breast cancer metastases. Aim of the present pilot study was to quantify PpIX-induced fluorescence of breast cancer metastases and correlate this with the hormone receptor status.

Methods: 5-ALA induced fluorescence intensity was quantified in 26 patients suffering from cerebral breast cancer metastases. A systematic spectrometric evaluation of tumor specimen and the resultant PpIX-induced fluorescence was performed using a spectrometer connected by optic fiber to a handheld probe. The difference between maximum PpIX-fluorescence at 635 nm and baseline fluorescence was considered as PpIX fluorescence intensity of the metastasis. In addition, results were correlated with receptor status (PD-L1, estrogen receptor, progesteron receptor, HER-2/neu) and histopathological examinations.

Results: All 26 patients had breast cancer with cerebral metastases. The mean age was 49 year (32 – 81 years). All patients were female. All 26 cerebral breast cancer metastases were considered as ALA fluorescent by the surgeon. A PpIX fluorescence over 1.1x106 AU was observed as “ALA-positive” by the surgeon. The mean PpIX fluorescence of analyzed cerebral breast cancer metastases was 3.4x106 AU (2.1x106 – 6.5x106 AU). After quantification we observed no significant difference in the levels of 5- ALA fluorescence in cerebral breast cancer metastases with different hormone receptor status.

Conclusion: Firstly, PpIX fluorescence over 1.1x106 AU was observed as “ALA-positive” by the surgeon. Secondly, all cerebral breast cancer metastases were tested as “ALA-positive” by the spectrometer. Thirdly, quantification of 5-ALA fluorescence showed no significant difference between cerebral breast cancer metastases with different hormone receptor status in our cohort.